×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Eris Lifesciences Limited | 6013.2 | 999.9 | 5786.4 | 7.33 | 23,312 | 60.2 |
| ASTRAZENECA PHARMA INDIA LTD. | 5375.5 | 558.3 | 5263.1 | 22.33 | 22500 | 106.0 |
| POLY MEDICURE LTD. | 4251.42 | 879.29 | 3840.47 | 8.67 | 20458 | 57.2 |
Eris Lifesciences Limited, with Security Code 540596, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 314.6 | 411.3 | 409.7 | 324.4 | 341.3 | 456.7 | 428.8 | 399.7 | 404.8 | 578.6 |
| Expenses | 203.1 | 255.8 | 265.2 | 250.0 | 261.9 | 333.3 | 293.9 | 300.2 | 283.8 | 362.3 |
| Operating Profit | 111.5 | 155.5 | 144.5 | 74.4 | 79.4 | 123.4 | 134.8 | 99.6 | 121.0 | 216.3 |
| OPM % | 35.44% | 37.81% | 35.27% | 22.94% | 23.26% | 27.02% | 31.44% | 24.91% | 29.9% | 37.38% |
| Other Income | 4.3 | 4.0 | 7.0 | 3.4 | 20.4 | 5.2 | 13.6 | 7.8 | 16.8 | 22.7 |
| Interest | 3.0 | 6.8 | 6.5 | 15.1 | 28.9 | 56.2 | 56.3 | 54.7 | 53.2 | 45.1 |
| Depreciation | 17.3 | 20.2 | 25.0 | 28.1 | 29.1 | 45.6 | 46.2 | 46.7 | 43.4 | 37.6 |
| Profit before tax | 95.5 | 132.5 | 119.9 | 34.6 | 41.7 | 26.8 | 46.0 | 6.0 | 41.2 | 156.3 |
| Tax % | -8% | -16.4% | -1.8% | -8.6% | -5.4% | 36.5% | -38.9% | -70.5% | -26% | 36% |
| Net Profit | 87.8 | 110.7 | 117.8 | 31.7 | 39.5 | 17.0 | 28.1 | 1.8 | 30.5 | 100.0 |
| EPS in Rs | 6.43 | 8.13 | 8.65 | 2.33 | 2.9 | 1.25 | 2.06 | 0.13 | 0 | 7.33 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 423.3 | 402.8 | 466.6 | 505.3 | 486.3 | 550.9 | 719.7 | 739.0 | 727.5 | 705.3 |
| Expenses | 286.1 | 283.9 | 296.9 | 324.2 | 310.8 | 402.5 | 469.7 | 476.7 | 477.1 | 452.9 |
| Operating Profit | 137.2 | 118.9 | 169.7 | 181.1 | 175.5 | 148.4 | 250.0 | 262.3 | 250.3 | 252.4 |
| OPM % | 32.42% | 29.52% | 36.38% | 35.85% | 36.09% | 26.94% | 34.73% | 35.49% | 34.41% | 35.79% |
| Other Income | 2.2 | 1.0 | 1.0 | 3.5 | 4.2 | 15.1 | 1.6 | 6.8 | 4.2 | 8.0 |
| Interest | 3.0 | 8.9 | 17.4 | 16.3 | 18.1 | 33.0 | 60.4 | 59.5 | 57.2 | 54.3 |
| Depreciation | 29.9 | 35.1 | 40.9 | 42.1 | 45.7 | 53.9 | 75.9 | 80.5 | 81.2 | 77.3 |
| Profit before tax | 106.5 | 75.9 | 112.5 | 126.2 | 115.9 | 76.6 | 115.3 | 129.1 | 116.2 | 128.9 |
| Tax % | -5.9% | -19% | -16.7% | -3.1% | -12.4% | 3.9% | -22.5% | 25.4% | 25.2% | -20.6% |
| Net Profit | 100.2 | 61.5 | 93.6 | 122.3 | 101.5 | 79.6 | 89.4 | 96.4 | 86.9 | 102.4 |
| EPS in Rs | 7.49 | 4.79 | 6.97 | 9.06 | 7.54 | 5.21 | 6.1 | 6.72 | 6.14 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 11% |
| 3 Years: | 12% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -23% |
| 3 Years: | -43% |
| TTM: | -74% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 25% |
| 3 Years: | 29% |
| 1 Year: | 67% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 22% |
| 3 Years: | 29% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 4% |
| 3 Years: | -5% |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 25% |
| 3 Years: | 29% |
| 1 Year: | 67% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|